Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol’s Next CEO Is Caforio, Tasked With Leading Immuno-Oncology Charge

Jan 21 2015

• By Lisa LaMotta

Related Content

Sanofi Should Take Note: Insiders Might Just Make Better CEOs

Dec 01 2014

What Medarex Has To Offer At $2.4 Billion

Aug 03 2009

Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity

Aug 02 2012

HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex

Jan 09 2012

$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership

Jun 30 2012

Bristol’s Take On Restructuring: Cut $1.5 Bil. In Costs, Try BioPharma Model

Dec 10 2007

With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol

May 01 2011

BMS CEO Jim Cornelius to Retire; Andreotti Named CEO

Mar 02 2010

Related Companies

Bristol Myers Squibb Company

Abbott

Medarex

Bristol Myers Squibb Company

AstraZeneca PLC

Additional Topics

Leadership Business Strategies Strategy BioPharmaceutical

More from Agency Leadership

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window